Visilizumab

• CAT Number: I042247
• CAS Number: 219716-33-3
• Purity: ≥95%

Visilizumab（Cat No.:I042247）is a monoclonal antibody that targets the CD3 receptor on T cells, playing a key role in immune cell activation. By binding to CD3, Visilizumab modulates the immune response, suppressing T-cell activity and reducing inflammation. It has been investigated primarily for autoimmune and inflammatory conditions, such as Crohn’s disease and ulcerative colitis, where an overactive immune response contributes to tissue damage. Visilizumab aims to provide therapeutic benefits by selectively inhibiting the pathogenic T-cell activation involved in these diseases. Clinical trials are ongoing to assess its efficacy, safety, and potential use in other autoimmune disorders.